6MD Stock Chart & Stats
€134.00
€0.00(0.00%)
At close: 4:00 PM EDT
€134.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€108.00 - €191.40
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€2.46B
Enterprise Value€2.98B
Total Cash (Recent Filing)€36.10M
Total Debt (Recent Filing)€321.58M
Price to Earnings (P/E)31.6
Beta0.63
Next Earnings
Mar 12, 2027EPS Estimate
2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.89
Shares Outstanding20,000,000
10 Day Avg. Volume5
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)7.36
Price to Sales (P/S)4.88
P/FCF Ratio112.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€160.45Price Target Upside19.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)5.22
Revenue Forecast (FY)€808.76M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMedacta released full fiscal year results that delivered a ~4% beat on Adjusted EBITDA, indicating strong financial performance.
Growth StrategyMedacta outlined a comprehensive growth strategy at their first CMD that hits the right notes around the current product opportunity set, execution and deliverable targets, and capital deployment.
Bears Say
Capital ExpenditureOperational free cash flow increased by 42%, indicating strong cash flow generation, even as capital expenditure rose, showing client traction in new product lines.
Medacta Group SA News
6MD FAQ
What was Medacta Group SA’s price range in the past 12 months?
Medacta Group SA lowest stock price was €108.00 and its highest was €191.40 in the past 12 months.
What is Medacta Group SA’s market cap?
Medacta Group SA’s market cap is €2.46B.
When is Medacta Group SA’s upcoming earnings report date?
Medacta Group SA’s upcoming earnings report date is Mar 12, 2027 which is in 152 days.
How were Medacta Group SA’s earnings last quarter?
Medacta Group SA released its earnings results on Sep 09, 2026. The company reported €2.1 earnings per share for the quarter.
Is Medacta Group SA overvalued?
According to Wall Street analysts Medacta Group SA’s price is currently Undervalued.
Does Medacta Group SA pay dividends?
Medacta Group SA does not currently pay dividends.
What is Medacta Group SA’s EPS estimate?
Medacta Group SA’s EPS estimate is 2.7.
How many shares outstanding does Medacta Group SA have?
Medacta Group SA has 20,000,000 shares outstanding.
What happened to Medacta Group SA’s price movement after its last earnings report?
Medacta Group SA reported an EPS of €2.1 in its last earnings report. Following the earnings report the stock price went down -5.344%.
Which hedge fund is a major shareholder of Medacta Group SA?
Currently, no hedge funds are holding shares in DE:6MD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medacta Group SA
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous other international markets, the company delivers specialized solutions. These include custom kinematic models and three-dimensional planning software, which are employed in various surgical procedures such as those for the hip, knee, and shoulder, as well as in sports medicine and spinal treatments. The firm, established in 1958, maintains its primary corporate office in Castel San Pietro, Switzerland.
6MD Company Deck
6MD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive, supported by almost 10% constant-currency revenue growth, above-market performance across most product categories and regions, confirmed 2026 and midterm guidance, product launches, India approval, and planned U.S. expansion. However, the period also included meaningful margin pressure, lower operating cash flow, negative free cash flow, a slower-than-expected U.S. market, customer attrition, Spanish strikes, and subdued spine growth. Highlights significantly outweighed the lowlights, although management acknowledged that reaching the midpoint of full-year guidance would be difficult.View all DE:6MD earnings summaries6MD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€160.45
▲(19.74% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Straumann Holding AG
―
Ypsomed Holding AG
―
medmix AG
―
Medartis Holding AG
―
Lepu Medical Technology (Beijing) Co., Ltd. Sponsored Global Depositary Receipt Repr Sh -A- Reg S
―











